Advanced peptide delivery

The Protixa™ ION System.

MicroAmino's pre-filled cartridges, pens, and nasal/oral sprays are formulated with the Protixa ION System — a cGMP protic ionic liquid (PIL) excipient platform engineered to stabilize peptides and enhance mucosal permeation in research models, without enzymatic degradation or loss of structural integrity.

The data below is preclinical, third-party characterization of the delivery excipient, provided for research context only. It is not a medical, therapeutic, or performance claim about any product. Research Use Only — professional / physician use only.

Stability report

How long Protixa Ion protects peptides.

Peptides are fragile — they degrade with heat, agitation, and enzymatic attack. In independent third-party HPLC testing, peptide formulated in the Protixa Ion matrix held its potency at room temperature across a multi-month study.

  • 101.1–101.9% recovery by HPLC — no measurable loss of potency
  • 4-month room-temperature stability study
  • No cold chain required for the Protixa matrix itself
  • ✓ Protease inhibition & aggregation control at the molecular level
Even though the Protixa matrix is room-temperature stable, MicroAmino ships and recommends storing pre-filled pens & cartridges refrigerated (2–8 °C) to protect the finished formulation. Lyophilized vials remain shelf-stable.
4MONTH

room-temperature stable

101%+HPLC recovery
No cold chainfor the matrix
Mechanism

A multi-mechanism delivery matrix.

The Protixa ION System organizes the formulation into nano-scale ionic assemblies that protect the peptide and move it across mucosal barriers in research models.

Molecular stabilization

Protic ionic liquid network inhibits proteases and controls aggregation, preserving peptide structure.

Sub-10 nm assemblies

A confirmed 5–10 nm secondary population (DLS) small enough to penetrate mucus gel networks that trap conventional formulations.

Mucus viscosity reduction

Reduces mucosal viscosity and modulates epithelial tight junctions (TEER reversibility) to open a transient permeation path.

Naturally-occurring build

Built from citric acid (a Krebs-cycle metabolite) + lysine & arginine — GRAS and USP/NF status, no novel synthetic entities.

Third-party characterization

The numbers.

>57×ex-vivo epithelial permeation vs. saline control
<10 nmsecondary nanoparticle population (DLS)
5 organsin-vivo systemic distribution within 1 hour (oral model)
80–100%cell viability — ISO 10993-5 CCK-8, non-cytotoxic
101.1–101.9%HPLC potency recovery, room temperature
GRAS · USP/NFpharmacopoeially accepted components
Manufacturing

Produced under cGMP.

The Protixa ION System is manufactured by Cell Wellness LLC (dba Protixa) in Rancho Cucamonga, California, under an NSF-assessed cGMP quality system.

  • ✓ NSF/ANSI 455-2 (2024) certified
  • ✓ 21 CFR Part 111, Part 117, Part 11 in scope
  • ✓ Formulation, encapsulation, packaging & QC under one quality unit
  • ✓ Every MicroAmino batch ships with a third-party COA
cGMP · NSF/ANSI 455-2

Certified facility

Manufactured under an NSF-assessed cGMP quality system in Rancho Cucamonga, CA. NSF/ANSI 455-2 certified; scope includes 21 CFR Parts 111, 117, 11, 1.5 Subpart L & 1.9 Subpart O.

Where it's used

Powered by Protixa Ion.

Every pre-filled format in the MicroAmino catalog is built on the Protixa ION System.

References & scope. Third-party studies: Zhejiang TianMei Biological Engineering Co., LTD and Zhejiang University of Technology. Peer-reviewed class reference: Angsantikul et al., Advanced Functional Materials (DOI: 10.1002/adfm.202002912). Data is preclinical; no human clinical data. Provided for laboratory research context only — not a medical, therapeutic, or performance claim.